Cargando…
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
BACKGROUND: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. METHODS: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. RESULTS: KIT...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856012/ https://www.ncbi.nlm.nih.gov/pubmed/20372153 http://dx.doi.org/10.1038/sj.bjc.6605635 |